ERBB2 and breast cancer: Relying upon preclinical evidence on the T-DXd bystander effect and the preliminary data from phase I, the Phase III DESTINY-Breast04 trial evaluated the efficacy of T-DXd in pre-treated patients with HER2-low metastatic BC who had received one or two lines of chemotherapy.